nodes	percent_of_prediction	percent_of_DWPC	metapath
Cysteamine—NPY2R—head—muscle cancer	0.0714	0.245	CbGeAlD
Cysteamine—SST—embryo—muscle cancer	0.055	0.189	CbGeAlD
Cysteamine—SST—smooth muscle tissue—muscle cancer	0.0433	0.149	CbGeAlD
Cysteamine—SST—renal system—muscle cancer	0.0417	0.143	CbGeAlD
Cysteamine—Gastrointestinal ulcer—Methotrexate—muscle cancer	0.0296	0.0537	CcSEcCtD
Cysteamine—SST—head—muscle cancer	0.0279	0.0958	CbGeAlD
Cysteamine—Gastrointestinal ulcer haemorrhage—Methotrexate—muscle cancer	0.0239	0.0433	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—MYF6—muscle cancer	0.0226	0.143	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—TP73—muscle cancer	0.0169	0.107	CbGpPWpGaD
Cysteamine—MPO—renal system—muscle cancer	0.0168	0.0577	CbGeAlD
Cysteamine—MPO—bone marrow—muscle cancer	0.0127	0.0436	CbGeAlD
Cysteamine—Optic neuritis—Etoposide—muscle cancer	0.0124	0.0225	CcSEcCtD
Cysteamine—MPO—head—muscle cancer	0.0112	0.0386	CbGeAlD
Cysteamine—MPO—testis—muscle cancer	0.0108	0.0373	CbGeAlD
Cysteamine—Appetite absent—Methotrexate—muscle cancer	0.0092	0.0167	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CD34—muscle cancer	0.009	0.057	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—MYOD1—muscle cancer	0.009	0.057	CbGpPWpGaD
Cysteamine—Lethargy—Dactinomycin—muscle cancer	0.00782	0.0142	CcSEcCtD
Cysteamine—Phosphatase alkaline increased—Etoposide—muscle cancer	0.00764	0.0139	CcSEcCtD
Cysteamine—Encephalopathy—Methotrexate—muscle cancer	0.00713	0.0129	CcSEcCtD
Cysteamine—Liver function test abnormal—Dactinomycin—muscle cancer	0.00708	0.0128	CcSEcCtD
Cysteamine—Pain in extremity—Vincristine—muscle cancer	0.00685	0.0124	CcSEcCtD
Cysteamine—SST—G alpha (i) signalling events—CNR1—muscle cancer	0.00662	0.042	CbGpPWpGaD
Cysteamine—Optic neuritis—Doxorubicin—muscle cancer	0.00644	0.0117	CcSEcCtD
Cysteamine—Ataxia—Vincristine—muscle cancer	0.00644	0.0117	CcSEcCtD
Cysteamine—Blood alkaline phosphatase increased—Etoposide—muscle cancer	0.00638	0.0116	CcSEcCtD
Cysteamine—Dehydration—Vincristine—muscle cancer	0.00637	0.0115	CcSEcCtD
Cysteamine—NPY2R—G alpha (i) signalling events—CNR1—muscle cancer	0.00635	0.0402	CbGpPWpGaD
Cysteamine—NPY2R—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.00589	0.0374	CbGpPWpGaD
Cysteamine—Redness—Doxorubicin—muscle cancer	0.00587	0.0106	CcSEcCtD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.00526	0.0334	CbGpPWpGaD
Cysteamine—Scotoma—Doxorubicin—muscle cancer	0.00522	0.00946	CcSEcCtD
Cysteamine—Bone disorder—Methotrexate—muscle cancer	0.00507	0.00919	CcSEcCtD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.00505	0.032	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—PTCH1—muscle cancer	0.00475	0.0301	CbGpPWpGaD
Cysteamine—Hallucination—Vincristine—muscle cancer	0.00471	0.00855	CcSEcCtD
Cysteamine—Urinary tract disorder—Vincristine—muscle cancer	0.00468	0.00848	CcSEcCtD
Cysteamine—Connective tissue disorder—Vincristine—muscle cancer	0.00466	0.00844	CcSEcCtD
Cysteamine—Urethral disorder—Vincristine—muscle cancer	0.00464	0.00842	CcSEcCtD
Cysteamine—Erythema—Dactinomycin—muscle cancer	0.00462	0.00837	CcSEcCtD
Cysteamine—NPY2R—GPCR ligand binding—PTCH1—muscle cancer	0.00455	0.0289	CbGpPWpGaD
Cysteamine—Bone disorder—Doxorubicin—muscle cancer	0.00439	0.00796	CcSEcCtD
Cysteamine—Thinking abnormal—Doxorubicin—muscle cancer	0.00433	0.00785	CcSEcCtD
Cysteamine—Anaemia—Dactinomycin—muscle cancer	0.00427	0.00774	CcSEcCtD
Cysteamine—Renal failure—Etoposide—muscle cancer	0.0042	0.00762	CcSEcCtD
Cysteamine—Mental disorder—Vincristine—muscle cancer	0.00415	0.00753	CcSEcCtD
Cysteamine—Leukopenia—Dactinomycin—muscle cancer	0.00413	0.00749	CcSEcCtD
Cysteamine—SST—GPCR ligand binding—CNR1—muscle cancer	0.00401	0.0254	CbGpPWpGaD
Cysteamine—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.00396	0.00719	CcSEcCtD
Cysteamine—Discomfort—Dactinomycin—muscle cancer	0.00388	0.00704	CcSEcCtD
Cysteamine—NPY2R—GPCR ligand binding—CNR1—muscle cancer	0.00384	0.0244	CbGpPWpGaD
Cysteamine—Anaemia—Vincristine—muscle cancer	0.00381	0.00691	CcSEcCtD
Cysteamine—Urinary tract disorder—Etoposide—muscle cancer	0.00379	0.00687	CcSEcCtD
Cysteamine—Agitation—Vincristine—muscle cancer	0.00379	0.00687	CcSEcCtD
Cysteamine—Urethral disorder—Etoposide—muscle cancer	0.00376	0.00682	CcSEcCtD
Cysteamine—Leukopenia—Vincristine—muscle cancer	0.00369	0.00669	CcSEcCtD
Cysteamine—SST—Signaling Pathways—KIDINS220—muscle cancer	0.00366	0.0232	CbGpPWpGaD
Cysteamine—Anorexia—Dactinomycin—muscle cancer	0.00359	0.00651	CcSEcCtD
Cysteamine—Convulsion—Vincristine—muscle cancer	0.00357	0.00648	CcSEcCtD
Cysteamine—Hypertension—Vincristine—muscle cancer	0.00356	0.00646	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—KIDINS220—muscle cancer	0.00351	0.0222	CbGpPWpGaD
Cysteamine—Immune system disorder—Etoposide—muscle cancer	0.00347	0.00628	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—KIT—muscle cancer	0.00344	0.0218	CbGpPWpGaD
Cysteamine—Mental disability—Doxorubicin—muscle cancer	0.00344	0.00624	CcSEcCtD
Cysteamine—Lethargy—Methotrexate—muscle cancer	0.00339	0.00615	CcSEcCtD
Cysteamine—Anaphylactic shock—Vincristine—muscle cancer	0.00337	0.0061	CcSEcCtD
Cysteamine—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.00331	0.006	CcSEcCtD
Cysteamine—Nervous system disorder—Vincristine—muscle cancer	0.0033	0.00598	CcSEcCtD
Cysteamine—Hepatic function abnormal—Doxorubicin—muscle cancer	0.00329	0.00597	CcSEcCtD
Cysteamine—Decreased appetite—Dactinomycin—muscle cancer	0.00327	0.00594	CcSEcCtD
Cysteamine—Fatigue—Dactinomycin—muscle cancer	0.00325	0.00589	CcSEcCtD
Cysteamine—Anorexia—Vincristine—muscle cancer	0.00321	0.00582	CcSEcCtD
Cysteamine—Eye pain—Doxorubicin—muscle cancer	0.00319	0.00578	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.00315	0.02	CbGpPWpGaD
Cysteamine—Mood swings—Methotrexate—muscle cancer	0.00315	0.00571	CcSEcCtD
Cysteamine—Ataxia—Methotrexate—muscle cancer	0.00312	0.00566	CcSEcCtD
Cysteamine—Feeling abnormal—Dactinomycin—muscle cancer	0.0031	0.00563	CcSEcCtD
Cysteamine—Anaemia—Etoposide—muscle cancer	0.00309	0.0056	CcSEcCtD
Cysteamine—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00308	0.00559	CcSEcCtD
Cysteamine—Liver function test abnormal—Methotrexate—muscle cancer	0.00307	0.00556	CcSEcCtD
Cysteamine—Leukopenia—Etoposide—muscle cancer	0.00299	0.00542	CcSEcCtD
Cysteamine—Abdominal pain—Dactinomycin—muscle cancer	0.00298	0.0054	CcSEcCtD
Cysteamine—Body temperature increased—Dactinomycin—muscle cancer	0.00298	0.0054	CcSEcCtD
Cysteamine—Lethargy—Doxorubicin—muscle cancer	0.00294	0.00532	CcSEcCtD
Cysteamine—Decreased appetite—Vincristine—muscle cancer	0.00293	0.0053	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Vincristine—muscle cancer	0.00291	0.00527	CcSEcCtD
Cysteamine—Fatigue—Vincristine—muscle cancer	0.0029	0.00526	CcSEcCtD
Cysteamine—Convulsion—Etoposide—muscle cancer	0.00289	0.00525	CcSEcCtD
Cysteamine—Hypertension—Etoposide—muscle cancer	0.00288	0.00523	CcSEcCtD
Cysteamine—Constipation—Vincristine—muscle cancer	0.00288	0.00522	CcSEcCtD
Cysteamine—Pain in extremity—Doxorubicin—muscle cancer	0.00288	0.00522	CcSEcCtD
Cysteamine—Affect lability—Doxorubicin—muscle cancer	0.00283	0.00513	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00282	0.00512	CcSEcCtD
Cysteamine—Discomfort—Etoposide—muscle cancer	0.00281	0.00509	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CDKN2A—muscle cancer	0.00279	0.0177	CbGpPWpGaD
Cysteamine—Hypersensitivity—Dactinomycin—muscle cancer	0.00278	0.00503	CcSEcCtD
Cysteamine—Gastrointestinal pain—Vincristine—muscle cancer	0.00275	0.00499	CcSEcCtD
Cysteamine—Confusional state—Etoposide—muscle cancer	0.00275	0.00498	CcSEcCtD
Cysteamine—Anaphylactic shock—Etoposide—muscle cancer	0.00273	0.00494	CcSEcCtD
Cysteamine—Mood swings—Doxorubicin—muscle cancer	0.00273	0.00494	CcSEcCtD
Cysteamine—Ataxia—Doxorubicin—muscle cancer	0.00271	0.00491	CcSEcCtD
Cysteamine—Asthenia—Dactinomycin—muscle cancer	0.0027	0.0049	CcSEcCtD
Cysteamine—Dehydration—Doxorubicin—muscle cancer	0.00268	0.00485	CcSEcCtD
Cysteamine—Abdominal pain—Vincristine—muscle cancer	0.00266	0.00482	CcSEcCtD
Cysteamine—Body temperature increased—Vincristine—muscle cancer	0.00266	0.00482	CcSEcCtD
Cysteamine—Liver function test abnormal—Doxorubicin—muscle cancer	0.00266	0.00482	CcSEcCtD
Cysteamine—Skin disorder—Etoposide—muscle cancer	0.00265	0.0048	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—PTGS2—muscle cancer	0.00261	0.0166	CbGpPWpGaD
Cysteamine—Anorexia—Etoposide—muscle cancer	0.0026	0.00471	CcSEcCtD
Cysteamine—Diarrhoea—Dactinomycin—muscle cancer	0.00258	0.00467	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—PTGS2—muscle cancer	0.00252	0.016	CbGpPWpGaD
Cysteamine—Renal failure—Methotrexate—muscle cancer	0.00252	0.00456	CcSEcCtD
Cysteamine—Hypersensitivity—Vincristine—muscle cancer	0.00248	0.0045	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—PTCH1—muscle cancer	0.00244	0.0155	CbGpPWpGaD
Cysteamine—Somnolence—Etoposide—muscle cancer	0.00242	0.00439	CcSEcCtD
Cysteamine—Asthenia—Vincristine—muscle cancer	0.00241	0.00438	CcSEcCtD
Cysteamine—Vomiting—Dactinomycin—muscle cancer	0.0024	0.00434	CcSEcCtD
Cysteamine—Rash—Dactinomycin—muscle cancer	0.00238	0.00431	CcSEcCtD
Cysteamine—Decreased appetite—Etoposide—muscle cancer	0.00237	0.0043	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Etoposide—muscle cancer	0.00235	0.00427	CcSEcCtD
Cysteamine—Fatigue—Etoposide—muscle cancer	0.00235	0.00426	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—PTCH1—muscle cancer	0.00234	0.0148	CbGpPWpGaD
Cysteamine—Constipation—Etoposide—muscle cancer	0.00233	0.00423	CcSEcCtD
Cysteamine—Diarrhoea—Vincristine—muscle cancer	0.0023	0.00418	CcSEcCtD
Cysteamine—Urinary tract disorder—Methotrexate—muscle cancer	0.00227	0.00412	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—CNR1—muscle cancer	0.00227	0.0144	CbGpPWpGaD
Cysteamine—Urethral disorder—Methotrexate—muscle cancer	0.00225	0.00409	CcSEcCtD
Cysteamine—Feeling abnormal—Etoposide—muscle cancer	0.00225	0.00407	CcSEcCtD
Cysteamine—Nausea—Dactinomycin—muscle cancer	0.00224	0.00406	CcSEcCtD
Cysteamine—Gastrointestinal pain—Etoposide—muscle cancer	0.00223	0.00404	CcSEcCtD
Cysteamine—Dizziness—Vincristine—muscle cancer	0.00223	0.00404	CcSEcCtD
Cysteamine—Renal failure—Doxorubicin—muscle cancer	0.00218	0.00395	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—CNR1—muscle cancer	0.00217	0.0138	CbGpPWpGaD
Cysteamine—Urticaria—Etoposide—muscle cancer	0.00217	0.00393	CcSEcCtD
Cysteamine—Body temperature increased—Etoposide—muscle cancer	0.00216	0.00391	CcSEcCtD
Cysteamine—Abdominal pain—Etoposide—muscle cancer	0.00216	0.00391	CcSEcCtD
Cysteamine—Vomiting—Vincristine—muscle cancer	0.00214	0.00388	CcSEcCtD
Cysteamine—Rash—Vincristine—muscle cancer	0.00212	0.00385	CcSEcCtD
Cysteamine—Dermatitis—Vincristine—muscle cancer	0.00212	0.00384	CcSEcCtD
Cysteamine—Headache—Vincristine—muscle cancer	0.00211	0.00382	CcSEcCtD
Cysteamine—Immune system disorder—Methotrexate—muscle cancer	0.00208	0.00376	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CNR1—muscle cancer	0.00206	0.013	CbGpPWpGaD
Cysteamine—Mental disorder—Methotrexate—muscle cancer	0.00201	0.00365	CcSEcCtD
Cysteamine—Hypersensitivity—Etoposide—muscle cancer	0.00201	0.00364	CcSEcCtD
Cysteamine—Erythema—Methotrexate—muscle cancer	0.002	0.00363	CcSEcCtD
Cysteamine—Malnutrition—Methotrexate—muscle cancer	0.002	0.00363	CcSEcCtD
Cysteamine—Nausea—Vincristine—muscle cancer	0.002	0.00362	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—CNR1—muscle cancer	0.00197	0.0125	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Doxorubicin—muscle cancer	0.00197	0.00356	CcSEcCtD
Cysteamine—Asthenia—Etoposide—muscle cancer	0.00196	0.00355	CcSEcCtD
Cysteamine—Connective tissue disorder—Doxorubicin—muscle cancer	0.00196	0.00355	CcSEcCtD
Cysteamine—Urethral disorder—Doxorubicin—muscle cancer	0.00195	0.00354	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—TP53—muscle cancer	0.00189	0.012	CbGpPWpGaD
Cysteamine—Diarrhoea—Etoposide—muscle cancer	0.00187	0.00338	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—TP53—muscle cancer	0.00186	0.0118	CbGpPWpGaD
Cysteamine—Anaemia—Methotrexate—muscle cancer	0.00185	0.00335	CcSEcCtD
Cysteamine—Dizziness—Etoposide—muscle cancer	0.0018	0.00327	CcSEcCtD
Cysteamine—Immune system disorder—Doxorubicin—muscle cancer	0.0018	0.00326	CcSEcCtD
Cysteamine—Leukopenia—Methotrexate—muscle cancer	0.00179	0.00325	CcSEcCtD
Cysteamine—Mental disorder—Doxorubicin—muscle cancer	0.00174	0.00316	CcSEcCtD
Cysteamine—Convulsion—Methotrexate—muscle cancer	0.00173	0.00314	CcSEcCtD
Cysteamine—Vomiting—Etoposide—muscle cancer	0.00173	0.00314	CcSEcCtD
Cysteamine—Malnutrition—Doxorubicin—muscle cancer	0.00173	0.00314	CcSEcCtD
Cysteamine—Erythema—Doxorubicin—muscle cancer	0.00173	0.00314	CcSEcCtD
Cysteamine—Rash—Etoposide—muscle cancer	0.00172	0.00312	CcSEcCtD
Cysteamine—Dermatitis—Etoposide—muscle cancer	0.00172	0.00311	CcSEcCtD
Cysteamine—Headache—Etoposide—muscle cancer	0.00171	0.0031	CcSEcCtD
Cysteamine—Tension—Doxorubicin—muscle cancer	0.0017	0.00308	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00169	0.00307	CcSEcCtD
Cysteamine—Discomfort—Methotrexate—muscle cancer	0.00168	0.00305	CcSEcCtD
Cysteamine—Nervousness—Doxorubicin—muscle cancer	0.00168	0.00305	CcSEcCtD
Cysteamine—Confusional state—Methotrexate—muscle cancer	0.00165	0.00299	CcSEcCtD
Cysteamine—Anaphylactic shock—Methotrexate—muscle cancer	0.00163	0.00296	CcSEcCtD
Cysteamine—Nausea—Etoposide—muscle cancer	0.00162	0.00294	CcSEcCtD
Cysteamine—Nervous system disorder—Methotrexate—muscle cancer	0.0016	0.0029	CcSEcCtD
Cysteamine—Anaemia—Doxorubicin—muscle cancer	0.0016	0.0029	CcSEcCtD
Cysteamine—Agitation—Doxorubicin—muscle cancer	0.00159	0.00289	CcSEcCtD
Cysteamine—Skin disorder—Methotrexate—muscle cancer	0.00159	0.00288	CcSEcCtD
Cysteamine—Anorexia—Methotrexate—muscle cancer	0.00156	0.00282	CcSEcCtD
Cysteamine—Leukopenia—Doxorubicin—muscle cancer	0.00155	0.00281	CcSEcCtD
Cysteamine—Convulsion—Doxorubicin—muscle cancer	0.0015	0.00272	CcSEcCtD
Cysteamine—Hypertension—Doxorubicin—muscle cancer	0.0015	0.00271	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00146	0.00266	CcSEcCtD
Cysteamine—Discomfort—Doxorubicin—muscle cancer	0.00146	0.00264	CcSEcCtD
Cysteamine—Somnolence—Methotrexate—muscle cancer	0.00145	0.00263	CcSEcCtD
Cysteamine—SST—Signaling Pathways—PTCH1—muscle cancer	0.00144	0.00913	CbGpPWpGaD
Cysteamine—Dyspepsia—Methotrexate—muscle cancer	0.00144	0.00261	CcSEcCtD
Cysteamine—Confusional state—Doxorubicin—muscle cancer	0.00143	0.00259	CcSEcCtD
Cysteamine—Decreased appetite—Methotrexate—muscle cancer	0.00142	0.00257	CcSEcCtD
Cysteamine—Anaphylactic shock—Doxorubicin—muscle cancer	0.00141	0.00256	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00141	0.00256	CcSEcCtD
Cysteamine—Fatigue—Methotrexate—muscle cancer	0.00141	0.00255	CcSEcCtD
Cysteamine—Nervous system disorder—Doxorubicin—muscle cancer	0.00139	0.00251	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—PTCH1—muscle cancer	0.00138	0.00875	CbGpPWpGaD
Cysteamine—Skin disorder—Doxorubicin—muscle cancer	0.00137	0.00249	CcSEcCtD
Cysteamine—Anorexia—Doxorubicin—muscle cancer	0.00135	0.00244	CcSEcCtD
Cysteamine—Feeling abnormal—Methotrexate—muscle cancer	0.00135	0.00244	CcSEcCtD
Cysteamine—Gastrointestinal pain—Methotrexate—muscle cancer	0.00134	0.00242	CcSEcCtD
Cysteamine—Urticaria—Methotrexate—muscle cancer	0.0013	0.00235	CcSEcCtD
Cysteamine—Body temperature increased—Methotrexate—muscle cancer	0.00129	0.00234	CcSEcCtD
Cysteamine—Abdominal pain—Methotrexate—muscle cancer	0.00129	0.00234	CcSEcCtD
Cysteamine—Somnolence—Doxorubicin—muscle cancer	0.00126	0.00228	CcSEcCtD
Cysteamine—Dyspepsia—Doxorubicin—muscle cancer	0.00124	0.00226	CcSEcCtD
Cysteamine—SST—Signaling Pathways—FOXO4—muscle cancer	0.00124	0.00785	CbGpPWpGaD
Cysteamine—Decreased appetite—Doxorubicin—muscle cancer	0.00123	0.00223	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00122	0.00221	CcSEcCtD
Cysteamine—Fatigue—Doxorubicin—muscle cancer	0.00122	0.00221	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CNR1—muscle cancer	0.00122	0.00771	CbGpPWpGaD
Cysteamine—Constipation—Doxorubicin—muscle cancer	0.00121	0.00219	CcSEcCtD
Cysteamine—Hypersensitivity—Methotrexate—muscle cancer	0.0012	0.00218	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—FOXO4—muscle cancer	0.00119	0.00753	CbGpPWpGaD
Cysteamine—Asthenia—Methotrexate—muscle cancer	0.00117	0.00212	CcSEcCtD
Cysteamine—Feeling abnormal—Doxorubicin—muscle cancer	0.00117	0.00211	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—CNR1—muscle cancer	0.00116	0.00739	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00116	0.0021	CcSEcCtD
Cysteamine—Urticaria—Doxorubicin—muscle cancer	0.00112	0.00204	CcSEcCtD
Cysteamine—Body temperature increased—Doxorubicin—muscle cancer	0.00112	0.00203	CcSEcCtD
Cysteamine—Abdominal pain—Doxorubicin—muscle cancer	0.00112	0.00203	CcSEcCtD
Cysteamine—Diarrhoea—Methotrexate—muscle cancer	0.00112	0.00203	CcSEcCtD
Cysteamine—Dizziness—Methotrexate—muscle cancer	0.00108	0.00196	CcSEcCtD
Cysteamine—Hypersensitivity—Doxorubicin—muscle cancer	0.00104	0.00189	CcSEcCtD
Cysteamine—Vomiting—Methotrexate—muscle cancer	0.00104	0.00188	CcSEcCtD
Cysteamine—Rash—Methotrexate—muscle cancer	0.00103	0.00187	CcSEcCtD
Cysteamine—Dermatitis—Methotrexate—muscle cancer	0.00103	0.00187	CcSEcCtD
Cysteamine—Headache—Methotrexate—muscle cancer	0.00102	0.00185	CcSEcCtD
Cysteamine—Asthenia—Doxorubicin—muscle cancer	0.00101	0.00184	CcSEcCtD
Cysteamine—SST—Signaling Pathways—IGF2—muscle cancer	0.000993	0.0063	CbGpPWpGaD
Cysteamine—Nausea—Methotrexate—muscle cancer	0.00097	0.00176	CcSEcCtD
Cysteamine—Diarrhoea—Doxorubicin—muscle cancer	0.000968	0.00175	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—IGF2—muscle cancer	0.000952	0.00604	CbGpPWpGaD
Cysteamine—Dizziness—Doxorubicin—muscle cancer	0.000935	0.0017	CcSEcCtD
Cysteamine—SST—Signaling Pathways—FOXO1—muscle cancer	0.000914	0.0058	CbGpPWpGaD
Cysteamine—Vomiting—Doxorubicin—muscle cancer	0.000899	0.00163	CcSEcCtD
Cysteamine—Rash—Doxorubicin—muscle cancer	0.000892	0.00162	CcSEcCtD
Cysteamine—Dermatitis—Doxorubicin—muscle cancer	0.000891	0.00162	CcSEcCtD
Cysteamine—Headache—Doxorubicin—muscle cancer	0.000886	0.00161	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—FOXO1—muscle cancer	0.000877	0.00556	CbGpPWpGaD
Cysteamine—Nausea—Doxorubicin—muscle cancer	0.00084	0.00152	CcSEcCtD
Cysteamine—SST—Signaling Pathways—KIT—muscle cancer	0.000697	0.00442	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—KIT—muscle cancer	0.000668	0.00424	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MDM2—muscle cancer	0.000549	0.00348	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MDM2—muscle cancer	0.000526	0.00334	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—VEGFA—muscle cancer	0.000417	0.00264	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—VEGFA—muscle cancer	0.000399	0.00253	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TP53—muscle cancer	0.000315	0.002	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TP53—muscle cancer	0.000302	0.00191	CbGpPWpGaD
